{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:07:48Z","timestamp":1790755668389,"version":"4.1.0"},"reference-count":60,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec><jats:title>Purpose of review<\/jats:title><jats:p>The current article reviews the recent advances in the field of myasthenia gravis, which span from autoantibody profiling and pathogenic mechanisms to therapy innovation. The overview is highlighting specifically the data and the needs of targeted treatments in the light of precision medicine in myasthenia gravis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Recent findings<\/jats:title><jats:p>Novel data published recently further increased our knowledge on myasthenia gravis. The use of cell-based assays has greatly improved autoantibody detection in myasthenia gravis patients, and the mechanisms of action of these antibodies have been described. The role of Toll-like receptor activation in the generation of thymic alterations and anti-acetylcholine receptor autosensitization has been further investigated implementing our understanding on the relationships between innate immunity and autoimmunity. Additional studies have been focused on the alterations of T-cell\/B-cell regulatory mechanisms in thymus and peripheral blood of myasthenia gravis patients. microRNAs and genetic factors are also emerging as key biomarkers in myasthenia gravis pathogenesis and prediction of drug efficacy in individual patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>The recent immunological and pathological findings in myasthenia gravis promise to improve myasthenia gravis treatment, via the development of more precise and personalized therapies.<\/jats:p><\/jats:sec>","DOI":"10.1097\/wco.0000000000000596","type":"journal-article","created":{"date-parts":[[2018,7,21]],"date-time":"2018-07-21T00:03:38Z","timestamp":1532131418000},"page":"517-525","source":"Crossref","is-referenced-by-count":76,"title":["Myasthenia gravis: from autoantibodies to therapy"],"prefix":"10.1097","volume":"31","author":[{"given":"Renato","family":"Mantegazza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Bernasconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Cavalcante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230925","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/nyas.13592","article-title":"Serological and experimental studies in different forms of myasthenia gravis","volume":"1413","author":"Vincent","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"R2-20230925","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/nyas.13519","article-title":"Thymus involvement in early-onset myasthenia gravis","volume":"1412","author":"Cron","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"R3-20230925","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis - autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"R4-20230925","doi-asserted-by":"crossref","first-page":"1756285617749134","DOI":"10.1177\/1756285617749134","article-title":"When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies","volume":"11","author":"Mantegazza","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"R5-20230925","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jneuroim.2015.04.015","article-title":"MuSK autoantibodies in myasthenia gravis detected by cell based assay\u2013A multinational study","volume":"284","author":"Tsonis","year":"2015","journal-title":"J Neuroimmunol"},{"key":"R6-20230925","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/nyas.13518","article-title":"Myasthenia gravis with antibodies to MuSK: an update","volume":"1412","author":"Evoli","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"R7-20230925","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann Neurol"},{"key":"R8-20230925","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00415-011-6194-7","article-title":"Anti-LRP4 autoantibodies in AChR- and MuSK-antibody negative myasthenia gravis","volume":"259","author":"Pevzner","year":"2012","journal-title":"J Neurol"},{"key":"R9-20230925","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis","volume":"52","author":"Zisimopoulou","year":"2014","journal-title":"J Autoimmun"},{"key":"R10-20230925","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1212\/NXI.0000000000000357","article-title":"IgG-specific cell-based assay detects potentially pathogenic MuSK-Abs in seronegative MG","volume":"4","author":"Huda","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R11-20230925","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/ene.13300","article-title":"Multiple antibody detection in \u2018seronegative\u2019 myasthenia gravis patients","volume":"24","author":"Hong","year":"2017","journal-title":"Eur J Neurol"},{"key":"R12-20230925","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.expneurol.2015.02.010","article-title":"Thymoma related myasthenia gravis in humans and potential animal models","volume":"270","author":"Marx","year":"2015","journal-title":"Exp Neurol"},{"key":"R13-20230925","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00415-017-8514-z","article-title":"Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis","volume":"264","author":"Cordts","year":"2017","journal-title":"J Neurol"},{"key":"R14-20230925","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ncl.2018.01.001","article-title":"Nature and action of antibodies in myasthenia gravis","volume":"36","author":"Ruff","year":"2018","journal-title":"Neurol Clin"},{"key":"R15-20230925","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.expneurol.2012.01.025","article-title":"Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects","volume":"234","author":"Viegas","year":"2012","journal-title":"Exp Neurol"},{"key":"R16-20230925","doi-asserted-by":"crossref","first-page":"20783","DOI":"10.1073\/pnas.1313944110","article-title":"MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4","volume":"110","author":"Huijbers","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"R17-20230925","doi-asserted-by":"crossref","first-page":"e80695","DOI":"10.1371\/journal.pone.0080695","article-title":"MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters","volume":"8","author":"Koneczny","year":"2013","journal-title":"PLoS One"},{"key":"R18-20230925","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/0167-5699(93)90244-F","article-title":"Defining criteria for autoimmune diseases (Witebsky's postulates revisited)","volume":"14","author":"Rose","year":"1993","journal-title":"Immunol Today"},{"key":"R19-20230925","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1172\/JCI66039","article-title":"Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis","volume":"123","author":"Shen","year":"2013","journal-title":"J Clin Invest"},{"key":"R20-20230925","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1080\/08820139.2017.1299754","article-title":"Immunization with recombinantly expressed lrp4 induces experimental autoimmune myasthenia gravis in C57BL\/6 mice","volume":"46","author":"Ulusoy","year":"2017","journal-title":"Immunol Invest"},{"key":"R21-20230925","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.expneurol.2017.08.006","article-title":"Immunization of mice with LRP4 induces myasthenia similar to MuSK-associated myasthenia gravis","volume":"297","author":"Mori","year":"2017","journal-title":"Exp Neurol"},{"key":"R22-20230925","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2014.05.001","article-title":"Myasthenia gravis: paradox versus paradigm in autoimmunity","volume":"52","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun"},{"key":"R23-20230925","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jaut.2013.12.013","article-title":"Innate immunity in myasthenia gravis thymus: pathogenic effects of Toll-like receptor 4 signaling on autoimmunity","volume":"52","author":"Cordiglieri","year":"2014","journal-title":"J Autoimmun"},{"key":"R24-20230925","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jaut.2013.12.016","article-title":"Central role of interferon-beta in thymic events leading to myasthenia gravis","volume":"52","author":"Cufi","year":"2014","journal-title":"J Autoimmun"},{"key":"R25-20230925","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/nyas.13534","article-title":"Toll-like receptors 7 and 9 in myasthenia gravis thymus: amplifiers of autoimmunity?","volume":"1413","author":"Cavalcante","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"R26-20230925","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/ana.21902","article-title":"Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus","volume":"67","author":"Cavalcante","year":"2010","journal-title":"Ann Neurol"},{"key":"R27-20230925","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.imbio.2015.12.007","article-title":"Increased expression of Toll-like receptors 7 and 9 in myasthenia gravis thymus characterized by active Epstein-Barr virus infection","volume":"221","author":"Cavalcante","year":"2016","journal-title":"Immunobiology"},{"key":"R28-20230925","article-title":"Detection of human parvovirus B19 infection in the thymus of patients with thymic hyperplasia-associated myasthenia gravis","author":"Gong","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"R29-20230925","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3389\/fimmu.2017.01029","article-title":"Use of Toll-like receptor agonists to induce ectopic lymphoid structures in myasthenia gravis mouse models","volume":"8","author":"Robinet","year":"2017","journal-title":"Front Immunol"},{"key":"R30-20230925","doi-asserted-by":"crossref","first-page":"95432","DOI":"10.18632\/oncotarget.20731","article-title":"Epstein-Barr virus in tumor-infiltrating B cells of myasthenia gravis thymoma: an innocent bystander or an autoimmunity mediator?","volume":"8","author":"Cavalcante","year":"2017","journal-title":"Oncotarget"},{"key":"R31-20230925","doi-asserted-by":"crossref","first-page":"73774","DOI":"10.18632\/oncotarget.17908","article-title":"Significance of B10 cell in patients with thymoma complicated with myasthenia gravis","volume":"8","author":"Lu","year":"2017","journal-title":"Oncotarget"},{"key":"R32-20230925","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/nyas.13591","article-title":"An imbalance between regulatory T cells and T helper 17 cells in acetylcholine receptor-positive myasthenia gravis patients","volume":"1413","author":"Villegas","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"R33-20230925","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.clim.2017.03.003","article-title":"CD4+ FoxP3+ T regulatory cell subsets in myasthenia gravis patients","volume":"179","author":"Kohler","year":"2017","journal-title":"Clin Immunol"},{"key":"R34-20230925","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.autrev.2013.07.003","article-title":"The role of miRNA in inflammation and autoimmunity","volume":"12","author":"Singh","year":"2013","journal-title":"Autoimmun Rev"},{"key":"R35-20230925","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.autrev.2018.01.008","article-title":"Analysis of microRNA expression in the thymus of Myasthenia Gravis patients opens new research avenues","volume":"17","author":"Cron","year":"2018","journal-title":"Autoimmun Rev"},{"key":"R36-20230925","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jneuroim.2018.03.021","article-title":"miR-548k regulates CXCL13 expression in myasthenia gravis patients with thymic hyperplasia and in Jurkat cells","volume":"320","author":"Li","year":"2018","journal-title":"J Neuroimmunol"},{"key":"R37-20230925","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10753-012-9526-6","article-title":"Possible involvement of toll-like receptors in the pathogenesis of myasthenia gravis","volume":"36","author":"Wang","year":"2013","journal-title":"Inflammation"},{"key":"R38-20230925","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.imbio.2016.06.012","article-title":"A novel infection- and inflammation-associated molecular signature in peripheral blood of myasthenia gravis patients","volume":"221","author":"Barzago","year":"2016","journal-title":"Immunobiology"},{"key":"R39-20230925","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jneuroim.2010.03.016","article-title":"Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients","volume":"225","author":"Masuda","year":"2010","journal-title":"J Neuroimmunol"},{"key":"R40-20230925","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1159\/000486037","article-title":"Increased proportion of Tc17 and Th17 cells and their significant reduction after thymectomy may be related to disease progression in myasthenia gravis","volume":"24","author":"Hosseini","year":"2017","journal-title":"Neuroimmunomodulation"},{"key":"R41-20230925","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.clineuro.2017.04.012","article-title":"Increased expression of P2X7 receptor in peripheral blood mononuclear cells correlates with clinical severity and serum levels of Th17-related cytokines in patients with myasthenia gravis","volume":"157","author":"Zhang","year":"2017","journal-title":"Clin Neurol Neurosurg"},{"key":"R42-20230925","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1080\/08916934.2018.1454913","article-title":"Altered expression of transcription factors IRF4 and IRF8 in peripheral blood B cells is associated with clinical severity and circulating plasma cells frequency in patients with myasthenia gravis","volume":"51","author":"Zhang","year":"2018","journal-title":"Autoimmunity"},{"key":"R43-20230925","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fneur.2017.00043","article-title":"Regulatory B cells in seropositive myasthenia gravis versus healthy controls","volume":"8","author":"Karim","year":"2017","journal-title":"Front Neurol"},{"key":"R44-20230925","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.4049\/jimmunol.1601415","article-title":"Dysregulation of B cell repertoire formation in myasthenia gravis patients revealed through deep sequencing","volume":"198","author":"Vander Heiden","year":"2017","journal-title":"J Immunol"},{"key":"R45-20230925","doi-asserted-by":"crossref","first-page":"e94263","DOI":"10.1172\/jci.insight.94263","article-title":"Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis","volume":"2","author":"Stathopoulos","year":"2017","journal-title":"JCI Insight"},{"key":"R46-20230925","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"R47-20230925","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N Engl J Med"},{"key":"R48-20230925","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0000000000004082","article-title":"A propensity score analysis for comparison of T-3b and VATET in myasthenia gravis","volume":"89","author":"Brenna","year":"2017","journal-title":"Neurology"},{"key":"R49-20230925","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3389\/fonc.2016.00214","article-title":"Report on First International Workshop on robotic surgery in thoracic oncology","volume":"6","author":"Veronesi","year":"2016","journal-title":"Front Oncol"},{"key":"R50-20230925","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3389\/fneur.2017.00230","article-title":"The role of osteopontin and its gene on glucocorticoid response in myasthenia gravis","volume":"8","author":"Xie","year":"2017","journal-title":"Front Neurol"},{"key":"R51-20230925","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/0091270011435989","article-title":"A new thiopurine S-methyltransferase haplotype associated with intolerance to azathioprine","volume":"53","author":"Colleoni","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"R52-20230925","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/FPC.0000000000000257","article-title":"A novel ABCC6 haplotype is associated with azathioprine drug response in myasthenia gravis","volume":"27","author":"Colleoni","year":"2017","journal-title":"Pharmacogenet Genomics"},{"key":"R53-20230925","doi-asserted-by":"crossref","first-page":"1049-e80","DOI":"10.1111\/ene.13652","article-title":"Dose optimisation of tacrolimus with therapeutic drug monitoring and CYP3A5 polymorphism in myasthenia gravis patients","volume":"25","author":"Chen","year":"2018","journal-title":"Eur J Neurol"},{"key":"R54-20230925","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"D\u00edaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"R55-20230925","doi-asserted-by":"crossref","first-page":"e1425","DOI":"10.1212\/WNL.0000000000005323","article-title":"Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis","volume":"90","author":"Hewett","year":"2018","journal-title":"Neurology"},{"key":"R56-20230925","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/acn3.51","article-title":"VAV1 and BAFF, via NF\u03baB pathway, are genetic risk factors for myasthenia gravis","volume":"1","author":"Avidan","year":"2014","journal-title":"Ann Clin Transl Neurol"},{"key":"R57-20230925","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"R58-20230925","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/aps.2015.91","article-title":"Toll-like receptors: potential targets for lupus treatment","volume":"36","author":"Wu","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"R59-20230925","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.autrev.2016.12.003","article-title":"TLRs, future potential therapeutic targets for RA","volume":"16","author":"Elshabrawy","year":"2017","journal-title":"Autoimmun Rev"},{"key":"R60-20230925","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1007\/s10753-017-0589-2","article-title":"Immature exosomes derived from microRNA-146a overexpressing dendritic cells act as antigen-specific therapy for myasthenia gravis","volume":"40","author":"Yin","year":"2017","journal-title":"Inflammation"}],"container-title":["Current Opinion in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00019052-201810000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T13:47:48Z","timestamp":1720446468000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00019052-201810000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/wco.0000000000000596","relation":{},"ISSN":["1350-7540","1473-6551"],"issn-type":[{"value":"1350-7540","type":"print"},{"value":"1473-6551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}